Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells
- 13 March 2009
- journal article
- Published by Wiley in Cell Proliferation
- Vol. 42 (2) , 229-240
Abstract
Objectives: The aim of this study was to investigate mechanisms involved in the growth inhibitory effect of silymarin, in humanhepatocellular carcinoma.Materials and Methods: The human hepatocellular carcinoma cell line HepG2 was utilized and the MTT assay was performed to study the antiproliferative effect of silymarin. Dual staining was undertaken for ethidium bromide/acridine orange, propidium iodide staining and DNA fragmentation studies were executed to confirm the presence of apoptosis. Cell‐cycle analysis was revealed by flow cytometry and mitochondrial transmembrane potential was measured by uptake of the mitochondrial‐specific lipophilic cationic dye rhodamine 123. Western blotting analysis for cytochrome c, p53, Bax, Bcl‐2, APAF‐1, caspase‐3, survivin, β‐catenin, cyclin D1, c‐Myc and PCNA was carried out.Results: Silymarin inhibited population growth of the hepatocellular carcinoma cells in a dose‐dependent manner, and the percentage of apoptotic cells was increased after treatment with 50 and 75 µg/ml silymarin for 24 h. Silymarin treatment increased the proportion of cells with reduced DNA content (sub‐G0/G1 or A0 peak), indicative of apoptosis with loss of cells in the G1 phase. Silymarin also decreased mitochondrial transmembrane potential of the cells, thereby increasing levels of cytosolic cytochrome c while up‐regulating expression of pro‐apoptotic proteins (such as p53, Bax, APAF‐1 and caspase‐3) with concomitant decrease in anti‐apoptotic proteins (Bcl‐2 and survivin) and proliferation‐associated proteins (β‐catenin, cyclin D1, c‐Myc and PCNA).Conclusions: Our results demonstrate that silymarin treatment inhibited proliferation and induced apoptosis in the human hepatocellular carcinoma cell line HepG2.Keywords
This publication has 52 references indexed in Scilit:
- Silymarin and epithelial cancer chemoprevention: How close we are to bedside?Toxicology and Applied Pharmacology, 2007
- HIF and c-Myc: Sibling Rivals for Control of Cancer Cell Metabolism and ProliferationCancer Cell, 2007
- Hepatocellular Carcinoma: Epidemiology and Molecular CarcinogenesisGastroenterology, 2007
- Suppression of N-nitrosodiethylamine induced hepatocarcinogenesis by silymarin in ratsChemico-Biological Interactions, 2006
- Killing cancer cells by flipping the Bcl-2/Bax switchCancer Cell, 2005
- Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell deathOncogene, 2000
- The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of ApoptosisScience, 1997
- Cancer Cell CyclesScience, 1996
- c-Myc and apoptosisBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1995
- Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liverJournal of Hepatology, 1989